NKGN VS RMTI Stock Comparison
Performance
NKGN10/100
10/100
NKGN returned -53.87% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
RMTI100/100
100/100
RMTI returned 42.03% in the last 12 months. Based on SPY's performance of -13.07%, its performance is above average giving it a score of 100 of 100.
Volatility
NKGN10/100
10/100
NKGN has had a lower than average amount of volatility over the last 12 months giving it a score of 10 of 100.
RMTI44/100
44/100
RMTI has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.
Analyst Price Targets
NKGN
"Analyst Price Targets" not found for NKGN
RMTI58/100
58/100
3 analysts offer 12-month price targets for RMTI. Together, they have an average target of 11, the most optimistic target put RMTI at 11 within 12-months and the most pessimistic has RMTI at 11.
Technicals
NKGN
"Technicals" not found for NKGN
RMTI57/100
57/100
RMTI receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
Earnings
NKGN
"Earnings" not found for NKGN
RMTI10/100
10/100
RMTI has missed earnings 7 times in the last 20 quarters.
Profit
NKGN
"Profit" not found for NKGN
RMTI10/100
10/100
Out of the last 20 quarters, RMTI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
All score calculations are broken down here to help you make more informed investing decisions
NKGen Biotech, Inc. Common Stock Summary
Nasdaq / NKGN
Healthcare
Biotechnology
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. Graf Acquisition Corp. IV was incorporated in 2021 and is based in The Woodlands, Texas.
Rockwell Medical, Inc. (DE) Common Stock Summary
Nasdaq / RMTI
Healthcare
Drug Manufacturers - Specialty & Generic
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NKGN to other companies in the same or a similar industry.